Semax
Synthetic ACTH(4-10) analog studied in neurotrophic research.
Category · BrainMech 6/10
View ProductAll pathwaysEmerging Moderate Emerging
Cellular energy & mitochondrial systems
Neurocognitive Peptide Research Pathway
Cognitive signaling and neural plasticity.
This pathway explores peptides studied for cognitive signaling, stress response, neuroprotection, and focus-related mechanisms.
System Overview
The biological system this pathway studies.
Cognitive performance and stress regulation depend on neurotrophic signaling (BDNF, NGF), synaptic plasticity, neurotransmitter systems (GABA, glutamate, monoamines), and neuroendocrine response. This pathway studies peptides that interact with these systems in models of learning, attention, mood-related signaling, and neuroprotection.
Educational research context · not medical advice
Why This Pathway Matters
Cognitive function emerges from neurotrophic signaling, plasticity, and stress regulation.
This pathway is studied to map how peptides influence BDNF-related signaling, synaptic plasticity, and neuroendocrine stress response. The work spans neuroprotection, focus-related models, and recovery of neural circuits in research settings.
Neurotrophic signaling
BDNF, NGF, and synaptic plasticity research.
Stress regulation
GABAergic and neuroendocrine modulation models.
Neuroprotection
Resilience of neurons and cognitive performance studies.
Educational research context · not medical advice
Research Progression Model
3 biological phases · click to explore
1
Research Phase 1
Cognitive Signaling
Research focus
Semax is studied for neurotrophic signaling, cognitive performance models, BDNF-related pathways, and neuroprotection research.
2
Research Phase 2
Stress Modulation
Research focus
Selank is studied for anxiolytic-like effects, stress modulation, GABA-related pathways, and immune-neuroendocrine signaling.
3
Research Phase 3
Neural Recovery
Research focus
These compounds are studied in neuroregeneration, synaptic plasticity, and cognitive function research.
Studied Compounds
Cerebrolysin
Moderate within specific neurological contextsSits within neurotrophic signaling pathways relevant to neurological recovery contexts.
Weeks to months for functional recovery endpoints in stroke contextsDihexa
Preclinical onlySits within HGF/c-Met signaling and synaptogenesis pathways in preclinical neural models.
Days to weeks in preclinical modelsMechanism Flow
How signaling unfolds across the three research phases.
Phase 1 covers the initial biological process. Phase 2 maps the signaling cascades downstream. Phase 3 describes systemic effects studied in research models.
1
Phase 1 · Neurotrophic signaling
- BDNF and NGF-related signaling research
- Synaptic plasticity and neuronal survival pathways
- Cognitive performance models in animals and small human studies
2
Phase 2 · Stress and neuromodulation
- GABAergic and serotonergic signaling models
- Anxiolytic-like effects in preclinical literature
- Immune-neuroendocrine interaction studies
3
Phase 3 · Neural recovery
- Neuroregeneration and synaptic remodeling research
- HGF-mimetic and angiotensin-IV system studies
- Cognitive recovery models post-injury or ischemia
Studied Compounds
Compounds studied within this pathway.
Each entry summarizes the mechanism explored in research literature. Not a recommendation, dosing guide, or protocol.
- SemaxEmerging
Studied for BDNF/NGF modulation and dopaminergic effects.
- SelankEmerging
Studied for GABAergic modulation and immune-neuroendocrine signaling.
- CerebrolysinModerate
Studied for neurotrophic-like activity in cognitive and stroke recovery research.
- DihexaEmerging
Studied for HGF/c-Met signaling and dendritic spine formation.
Research Observation Timeline Across This Pathway
Timeline patterns measured in studies of these compounds.
Every compound in this pathway has a primary study window described in the research literature. Windows below describe research observation periods only — not expected personal outcomes.
Emerging · 2Moderate within specific neurological contexts · 1Preclinical only · 1
- SemaxEmerging
Measured in studies: Days to weeks in preclinical and regional clinical studies
Endpoint type · Gene expression, behavioral, and clinical scale endpoints
- SelankEmerging
Measured in studies: Days to weeks in preclinical and regional clinical contexts
Endpoint type · Behavioral and gene expression endpoints
- CerebrolysinModerate within specific neurological contexts
Measured in studies: Weeks to months for functional recovery endpoints in stroke contexts
Endpoint type · Clinical functional recovery scales and biomarker endpoints
- DihexaPreclinical only
Measured in studies: Days to weeks in preclinical models
Endpoint type · Cellular and behavioral preclinical endpoints
These windows reflect research observation periods only, not guaranteed personal outcomes.
Research Insights
What current research focuses on.
- Russian research literature accounts for much of the Semax/Selank evidence base.
- Cerebrolysin has the largest human data set in this group, primarily in stroke and neurodegenerative settings.
- Mechanistic plausibility (BDNF, plasticity) is stronger than translational performance data in healthy populations.
Research Limitations
Where the evidence base is incomplete.
- Independent replication outside originating research groups is limited.
- Long-term cognitive and safety outcomes are not well characterized.
- Healthy-population studies are sparse compared to clinical-population data.
Transparency note · evidence gaps disclosed for research integrity
Research Relationship Overview
How these compounds are studied together.
Each phase groups compounds with mechanistic overlap. The diagram shows which compounds are explored in combination within published research literature — not a recommended use strategy.
Pathway hubResearch phaseStudied compoundMechanistic overlap
DisclaimerThis visualization reflects research relationships and does not represent a recommended use strategy. Compounds shown here are studied together in research contexts only — this is not a protocol, dosing guide, or medical advice.
Catalog · Research compounds
Related Compounds Available
Compounds referenced in this pathway's research literature. Each links to its full Library profile — mechanism, evidence, and research context. Research use only.
Emerging
Selank
Synthetic tuftsin analog studied in anxiolytic-like research.
Category · BrainMech 6/10
View ProductCerebrolysin
Neuropeptide preparation studied in neuroregeneration research.
Category · BrainMech 6/10
View ProductDihexa
Angiotensin IV analog studied in synaptogenesis research.
Category · BrainMech 5/10
View ProductFor research use only · Not for human consumption
For research and educational purposes only.
Not medical advice. Not intended to diagnose, treat, cure, or prevent disease. Compounds discussed may not be approved for human use. Any dosing information shown describes ranges studied in research settings — never a recommendation.